IL125413A - Oxa-thea-diazole competing muscarinic receptor, their preparation and pharmaceutical mixtures containing them - Google Patents

Oxa-thea-diazole competing muscarinic receptor, their preparation and pharmaceutical mixtures containing them

Info

Publication number
IL125413A
IL125413A IL12541397A IL12541397A IL125413A IL 125413 A IL125413 A IL 125413A IL 12541397 A IL12541397 A IL 12541397A IL 12541397 A IL12541397 A IL 12541397A IL 125413 A IL125413 A IL 125413A
Authority
IL
Israel
Prior art keywords
compound
formula
alkyl
phenyl
pharmaceutically acceptable
Prior art date
Application number
IL12541397A
Other languages
English (en)
Hebrew (he)
Other versions
IL125413A0 (en
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of IL125413A0 publication Critical patent/IL125413A0/xx
Publication of IL125413A publication Critical patent/IL125413A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
IL12541397A 1996-02-22 1997-02-04 Oxa-thea-diazole competing muscarinic receptor, their preparation and pharmaceutical mixtures containing them IL125413A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9603755.1A GB9603755D0 (en) 1996-02-22 1996-02-22 Therapeutic agents
PCT/EP1997/000525 WO1997030994A1 (en) 1996-02-22 1997-02-04 Oxa- and thia-diazole muscarinic receptor antagonists

Publications (2)

Publication Number Publication Date
IL125413A0 IL125413A0 (en) 1999-03-12
IL125413A true IL125413A (en) 2002-09-12

Family

ID=10789217

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12541397A IL125413A (en) 1996-02-22 1997-02-04 Oxa-thea-diazole competing muscarinic receptor, their preparation and pharmaceutical mixtures containing them

Country Status (43)

Country Link
US (1) US5977142A (xx)
EP (1) EP0885218B1 (xx)
JP (1) JP3148252B2 (xx)
KR (1) KR100315934B1 (xx)
CN (1) CN1089340C (xx)
AP (1) AP751A (xx)
AR (1) AR005916A1 (xx)
AT (1) ATE200899T1 (xx)
AU (1) AU712230B2 (xx)
BG (2) BG63971B1 (xx)
BR (1) BR9707733A (xx)
CA (1) CA2247164C (xx)
CO (1) CO4650040A1 (xx)
CZ (1) CZ292650B6 (xx)
DE (1) DE69704701T2 (xx)
DK (1) DK0885218T3 (xx)
DZ (1) DZ2181A1 (xx)
ES (1) ES2156357T3 (xx)
GB (1) GB9603755D0 (xx)
GR (1) GR3036032T3 (xx)
HK (1) HK1018274A1 (xx)
HN (1) HN1997000020A (xx)
HR (1) HRP970098B1 (xx)
HU (1) HUP9900501A3 (xx)
ID (1) ID16642A (xx)
IL (1) IL125413A (xx)
IS (1) IS4803A (xx)
MY (1) MY129729A (xx)
NO (1) NO313414B1 (xx)
NZ (1) NZ331039A (xx)
OA (1) OA10838A (xx)
PE (1) PE42798A1 (xx)
PL (1) PL186879B1 (xx)
PT (1) PT885218E (xx)
RU (1) RU2162848C2 (xx)
SK (1) SK283461B6 (xx)
TN (1) TNSN97039A1 (xx)
TR (1) TR199801644T2 (xx)
TW (1) TW492961B (xx)
UA (1) UA61068C2 (xx)
WO (1) WO1997030994A1 (xx)
YU (1) YU35698A (xx)
ZA (1) ZA971513B (xx)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0516313D0 (en) * 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
WO2008017827A2 (en) * 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
JP2010501533A (ja) * 2006-08-21 2010-01-21 アージェンタ ディスカバリー リミテッド Ｍ３レセプター調節物質として有用な窒素含有複素環化合物
WO2008096093A1 (en) * 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
GB0702416D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
MX2009008364A (es) * 2007-02-07 2009-08-20 Astrazeneca Ab Sal de napadisilato de un antagonista m3 muscarinico.
GB0702414D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702385D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702382D0 (en) * 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
MX2009008323A (es) * 2007-02-15 2009-08-13 Argenta Discovery Ltd Derivados heterociclicos como receptores muscarinicos m3.
WO2009098453A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
US8263623B2 (en) 2008-07-11 2012-09-11 Pfizer Inc. Triazol derivatives useful for the treatment of diseases
WO2010018352A1 (en) * 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
JP2014065387A (ja) * 2012-09-25 2014-04-17 Showa Corp 自動二輪車の車高調整装置

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ219646A (en) * 1986-03-27 1990-10-26 Merck Sharp & Dohme Oxadiazole derivatives of azacyclics for treating cns disorders
IL88846A0 (en) * 1988-01-08 1989-07-31 Merck Sharp & Dohme Lipophilic oxadiazoles,their preparation and pharmaceutical compositions containing them
US5043345A (en) * 1989-02-22 1991-08-27 Novo Nordisk A/S Piperidine compounds and their preparation and use
US5622976A (en) * 1991-12-31 1997-04-22 Fujisawa Pharmaceutical Co., Ltd. Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
TW360653B (en) * 1995-03-01 1999-06-11 Janssen Pharmaceutica Nv A oxadiazole compound having colon motility stimulating properties, its preparation process and its pharmaceutical composition

Also Published As

Publication number Publication date
PT885218E (pt) 2001-08-30
PL186879B1 (pl) 2004-03-31
HK1018274A1 (en) 1999-12-17
IS4803A (is) 1998-07-21
BR9707733A (pt) 1999-07-27
GB9603755D0 (en) 1996-04-24
KR100315934B1 (ko) 2002-03-21
RU2162848C2 (ru) 2001-02-10
AU1601497A (en) 1997-09-10
BG102699A (en) 1999-09-30
BG63971B1 (bg) 2003-08-29
AU712230B2 (en) 1999-11-04
SK283461B6 (sk) 2003-08-05
TW492961B (en) 2002-07-01
US5977142A (en) 1999-11-02
NO313414B1 (no) 2002-09-30
CN1089340C (zh) 2002-08-21
CZ267898A3 (cs) 1999-08-11
TNSN97039A1 (fr) 2005-03-15
NZ331039A (en) 1999-10-28
NO983871D0 (no) 1998-08-21
JPH11504051A (ja) 1999-04-06
ES2156357T3 (es) 2001-06-16
CN1211981A (zh) 1999-03-24
CO4650040A1 (es) 1998-09-03
EP0885218A1 (en) 1998-12-23
HRP970098B1 (en) 2001-12-31
ATE200899T1 (de) 2001-05-15
DE69704701T2 (de) 2001-08-16
AP9700930A0 (en) 1997-04-30
AP751A (en) 1999-07-12
CZ292650B6 (cs) 2003-11-12
DE69704701D1 (de) 2001-06-07
SK112398A3 (en) 2000-04-10
IL125413A0 (en) 1999-03-12
DK0885218T3 (da) 2001-05-28
UA61068C2 (en) 2003-11-17
HUP9900501A2 (hu) 1999-06-28
PE42798A1 (es) 1998-08-18
TR199801644T2 (xx) 1998-11-23
CA2247164C (en) 2004-11-16
PL328633A1 (en) 1999-02-15
AR005916A1 (es) 1999-07-21
EP0885218B1 (en) 2001-05-02
KR19990087143A (ko) 1999-12-15
NO983871L (no) 1998-08-21
HUP9900501A3 (en) 2001-02-28
GR3036032T3 (en) 2001-09-28
HRP970098A2 (en) 1999-04-30
ZA971513B (en) 1998-08-21
YU35698A (sh) 1999-07-28
CA2247164A1 (en) 1997-08-28
WO1997030994A1 (en) 1997-08-28
JP3148252B2 (ja) 2001-03-19
ID16642A (id) 1997-10-23
MY129729A (en) 2007-04-30
OA10838A (en) 2001-08-13
HN1997000020A (es) 1997-06-05
DZ2181A1 (fr) 2002-12-01

Similar Documents

Publication Publication Date Title
IL125413A (en) Oxa-thea-diazole competing muscarinic receptor, their preparation and pharmaceutical mixtures containing them
Moltzen et al. Bioisosteres of arecoline: 1, 2, 3, 6-tetrahydro-5-pyridyl-substituted and 3-piperidyl-substituted derivatives of tetrazoles and 1, 2, 3-triazoles. Synthesis and muscarinic activity
US5496833A (en) Piperidine tachykinin receptor antagonists
US5668148A (en) Alpha1a adrenergic receptor antagonists
JP2003503311A (ja) 置換アゾール類
JPH09501439A (ja) ニューロキニンアンタゴニストとして有用な複素環
US5444074A (en) Piperidine tachykinin receptor antagonists
BR112015004511B1 (pt) Derivados de pirazol carboxamida como moduladores de taar para uso no tratamento de diversas desordens, tais como depressão, diabetes e doença de parkinson
JP2002532480A (ja) モルホリノン及びモルホリン誘導体、ならびにその使用
US5486527A (en) Anticholinergic agents
CA2072575C (en) Anticholinergic agents
CA2309485C (en) New 4-arylpiperidine derivatives for the treatment of pruritus
JP2002504082A (ja) アレルギー疾患の治療に有用な新規な置換されたｎ―メチル―ｎ―（４―（ピペリジン―１―イル）―２―（アリール）ブチル）ベンズアミド
EP0505379B1 (en) Muscarinic receptor antagonists
CA2573446A1 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
MXPA05002366A (es) Compuestos benzoil piperidina novedosos.
MXPA00005290A (en) 4-arylpiperidine derivatives for the treatment of pruritus
MXPA98006839A (en) Antagonists oxadiazol and tiadiazol of the muscarin receiver
JP2003510321A (ja) セロトニン再取込み抑制薬としてのピペリジン誘導体

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees